Immunophenotypic shift in the B ‐cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B ‐lymphoblastic leukemia-Reference-Cited by-同舟云学术

Immunophenotypic shift in the B ‐cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B ‐lymphoblastic leukemia

Published:2020-09-08 Issue: Volume: Page:
ISSN:1552-4949
Container-title:Cytometry Part B: Clinical Cytometry
language:en
Short-container-title:Cytometry

Author:

Chatterjee Gaurav¹^ORCID,Sriram Harshini¹,Ghogale Sitaram¹,Deshpande Nilesh¹,Khanka Twinkle¹,Panda Devasis¹,Pradhan Shiv Narayan¹,Girase Karishma¹,Narula Gaurav²,Dhamane Chetan²,Malik Nirmlya Roy²,Banavali Shripad²,Patkar Nikhil V.¹,Gujral Sumeet³,Subramanian Papagudi G.¹,Tembhare Prashant R.¹^ORCID

Affiliation:

1. Hematopathology Laboratory, ACTREC, Tata Memorial Center HBNI University Navi Mumbai India

2. Department of Pediatric Oncology Tata Memorial Center, HBNI University Mumbai India

3. Hematopathology Laboratory Tata Memorial Center, HBNI University Mumbai India

Publisher

Wiley

Subject

Cell Biology,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cyto.b.21951

Reference45 articles.

1. Hematogones in acute leukemia during and after therapy

2. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

3. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection

4. Minimal residual disease–guided therapy in childhood acute lymphoblastic leukemia

5. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: Implications for minimal residual disease detection;Ciudad J.;Haematologica,1998

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maturational dyssynchrony in benign B‐cell precursors following lymphocyte depleting chemotherapy: A potential pitfall for B‐lymphoblastic leukemia minimal/measurable residual disease (MRD) flow cytometry analysis;Cytometry Part B: Clinical Cytometry;2024-01-21

2. Deciphering stage 0 hematogones by flow cytometry in follow‐up bone marrow samples of pediatric B—Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy;Cytometry Part B: Clinical Cytometry;2024-01-19

3. Analytical Appraisal of Hematogones in B-ALL MRD Assessment Using Multidimensional Dot-Plots by Multiparametric Flow Cytometry: A Critical Review and Update;Indian Journal of Hematology and Blood Transfusion;2023-09-16

4. 15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic leukemia/lymphoma: Real‐world applicability and challenges;European Journal of Haematology;2023-09-14

5. Flow Cytometric MRD Assessment in Acute Lymphoblastic Leukemias;Indian Journal of Medical and Paediatric Oncology;2023-04-17